NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications CNS cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms MATCH
- 01 Oct 2019 Planned End Date changed from 30 Mar 2023 to 30 Jun 2025.
- 01 Oct 2019 Planned primary completion date changed from 30 Mar 2023 to 30 Jun 2025.
- 06 Jul 2018 Status changed from not yet recruiting to recruiting.